JP2006510728A - 糖尿病の処置に有用なアニリノピラゾール誘導体 - Google Patents
糖尿病の処置に有用なアニリノピラゾール誘導体 Download PDFInfo
- Publication number
- JP2006510728A JP2006510728A JP2004570952A JP2004570952A JP2006510728A JP 2006510728 A JP2006510728 A JP 2006510728A JP 2004570952 A JP2004570952 A JP 2004570952A JP 2004570952 A JP2004570952 A JP 2004570952A JP 2006510728 A JP2006510728 A JP 2006510728A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkoxy
- alkyl
- group
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1n[n](*)c(N)c1 Chemical compound *c1n[n](*)c(N)c1 0.000 description 4
- OWXZWQMOHYSDOW-UHFFFAOYSA-N CC(C)(C)c(cc1N(C)c(ccc(OC)c2)c2C(O)=O)n[n]1-c1c(C)cccc1C Chemical compound CC(C)(C)c(cc1N(C)c(ccc(OC)c2)c2C(O)=O)n[n]1-c1c(C)cccc1C OWXZWQMOHYSDOW-UHFFFAOYSA-N 0.000 description 1
- UWXMVXSLUXRJJW-UHFFFAOYSA-N CCc(cc1)cc(C(OC)=O)c1Nc1cc(C(C)C(C)C)n[n]1-c1ccccc1C Chemical compound CCc(cc1)cc(C(OC)=O)c1Nc1cc(C(C)C(C)C)n[n]1-c1ccccc1C UWXMVXSLUXRJJW-UHFFFAOYSA-N 0.000 description 1
- JNZIOSPCYNMBET-XZOQPEGZSA-N C[C@@H](c(c(C(OC)=O)c1)ccc1OC)N(C)C([C@@H](C)[N+2](c1ccccc1C)N=C1C)=C1c1ccccc1 Chemical compound C[C@@H](c(c(C(OC)=O)c1)ccc1OC)N(C)C([C@@H](C)[N+2](c1ccccc1C)N=C1C)=C1c1ccccc1 JNZIOSPCYNMBET-XZOQPEGZSA-N 0.000 description 1
- RUQPFGKGRKRLQJ-UHFFFAOYSA-N Cc1c(Nc(ccc(C)c2)c2C(O)=O)[n](-c2c(C)cccc2)nc1-c1ccc(C)cc1 Chemical compound Cc1c(Nc(ccc(C)c2)c2C(O)=O)[n](-c2c(C)cccc2)nc1-c1ccc(C)cc1 RUQPFGKGRKRLQJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42991702P | 2002-11-27 | 2002-11-27 | |
| US49821403P | 2003-08-27 | 2003-08-27 | |
| PCT/US2003/037829 WO2004050651A1 (en) | 2002-11-27 | 2003-11-25 | Anilinopyrazole derivatives useful for the treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510728A true JP2006510728A (ja) | 2006-03-30 |
| JP2006510728A5 JP2006510728A5 (https=) | 2007-01-11 |
Family
ID=32474531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004570952A Pending JP2006510728A (ja) | 2002-11-27 | 2003-11-25 | 糖尿病の処置に有用なアニリノピラゾール誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7265144B2 (https=) |
| EP (1) | EP1567517A1 (https=) |
| JP (1) | JP2006510728A (https=) |
| KR (1) | KR20050085170A (https=) |
| AR (1) | AR042067A1 (https=) |
| AU (2) | AU2003295890A1 (https=) |
| BR (1) | BR0316723A (https=) |
| CA (1) | CA2507186A1 (https=) |
| HN (1) | HN2003000379A (https=) |
| MX (1) | MXPA05004621A (https=) |
| MY (1) | MY141528A (https=) |
| PE (1) | PE20040907A1 (https=) |
| PL (1) | PL377164A1 (https=) |
| TW (1) | TW200418803A (https=) |
| UY (1) | UY28098A1 (https=) |
| WO (2) | WO2004050650A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008093639A1 (ja) * | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| JP2013536866A (ja) * | 2010-09-01 | 2013-09-26 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌・殺カビ性ピラゾールおよびその混合物 |
| WO2016204270A1 (ja) * | 2015-06-18 | 2016-12-22 | 日本曹達株式会社 | ジアリールアゾール化合物および有害生物防除剤 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007538102A (ja) * | 2004-05-20 | 2007-12-27 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体 |
| ES2395952T3 (es) | 2005-03-16 | 2013-02-18 | Toyama Chemical Co., Ltd. | Nuevo derivado del ácido antranílico o una sal del mismo |
| JP5193861B2 (ja) * | 2005-07-07 | 2013-05-08 | アボット・ラボラトリーズ | アポトーシス促進剤 |
| CA2620425A1 (en) * | 2005-08-31 | 2007-03-08 | Bayer Healthcare Llc | Anilinopyrazole derivatives useful for the treatment of diabetes |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| US8022217B2 (en) | 2006-07-31 | 2011-09-20 | Cadila Healthcare Limited | Compounds suitable as modulators of HDL |
| WO2008042639A1 (en) | 2006-10-02 | 2008-04-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US20110034521A1 (en) * | 2007-09-28 | 2011-02-10 | Alan Jacobson | Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
| DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
| CA2737437A1 (en) * | 2008-09-19 | 2010-03-25 | Absolute Science, Inc. | Methods of treating a botulinum toxin related condition in a subject |
| WO2010034657A1 (en) * | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives |
| AR075713A1 (es) | 2009-03-03 | 2011-04-20 | Du Pont | Pirazoles fungicidas |
| TWI568721B (zh) | 2012-02-01 | 2017-02-01 | 杜邦股份有限公司 | 殺真菌之吡唑混合物 |
| WO2014007228A1 (ja) * | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| CN103074693A (zh) * | 2013-01-18 | 2013-05-01 | 桐昆集团股份有限公司 | 带双导丝辊的poy纺丝卷绕装置 |
| EP3663287B1 (en) | 2013-12-23 | 2023-09-20 | Amazentis SA | Process scale synthesis of urolithins |
| EP3632904B1 (en) * | 2017-05-26 | 2022-04-20 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. | Urat1 inhibitors for promoting uric acid excretion |
| US11312722B2 (en) * | 2019-05-08 | 2022-04-26 | Trustees Of Boston University | Hsp90 inhibitors and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257410A (en) * | 1960-04-14 | 1966-06-21 | Bayer Ag | N-pyrazoyl anthranilic acid derivatives and their synthesis |
| US3790576A (en) * | 1972-03-20 | 1974-02-05 | Parke Davis & Co | 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019054A1 (en) | 1992-03-26 | 1993-09-30 | Dowelanco | N-heterocyclic nitro anilines as fungicides |
| WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| DE19532066A1 (de) | 1995-08-31 | 1997-03-06 | Bayer Ag | Substituierte 5-Aminopyrazole |
| FR2763334A1 (fr) | 1997-05-13 | 1998-11-20 | Lipha | Derives anthraniliques |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US5942520A (en) | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
| WO2004076414A2 (en) * | 2003-02-27 | 2004-09-10 | Smithkline Beecham Corporation | Novel compounds |
-
2003
- 2003-11-18 AR ARP030104252A patent/AR042067A1/es unknown
- 2003-11-21 US US10/719,485 patent/US7265144B2/en not_active Expired - Fee Related
- 2003-11-21 WO PCT/US2003/037578 patent/WO2004050650A1/en not_active Ceased
- 2003-11-21 AU AU2003295890A patent/AU2003295890A1/en not_active Abandoned
- 2003-11-25 KR KR1020057009560A patent/KR20050085170A/ko not_active Withdrawn
- 2003-11-25 JP JP2004570952A patent/JP2006510728A/ja active Pending
- 2003-11-25 PL PL377164A patent/PL377164A1/pl not_active Application Discontinuation
- 2003-11-25 BR BR0316723-2A patent/BR0316723A/pt not_active IP Right Cessation
- 2003-11-25 MX MXPA05004621A patent/MXPA05004621A/es not_active Application Discontinuation
- 2003-11-25 WO PCT/US2003/037829 patent/WO2004050651A1/en not_active Ceased
- 2003-11-25 AU AU2003297565A patent/AU2003297565A1/en not_active Abandoned
- 2003-11-25 EP EP03812454A patent/EP1567517A1/en not_active Withdrawn
- 2003-11-25 CA CA002507186A patent/CA2507186A1/en not_active Abandoned
- 2003-11-26 TW TW092133242A patent/TW200418803A/zh unknown
- 2003-11-26 PE PE2003001198A patent/PE20040907A1/es not_active Application Discontinuation
- 2003-11-26 UY UY28098A patent/UY28098A1/es not_active Application Discontinuation
- 2003-11-26 HN HN2003000379A patent/HN2003000379A/es unknown
- 2003-11-27 MY MYPI20034545A patent/MY141528A/en unknown
-
2007
- 2007-08-31 US US11/897,620 patent/US20080064734A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257410A (en) * | 1960-04-14 | 1966-06-21 | Bayer Ag | N-pyrazoyl anthranilic acid derivatives and their synthesis |
| US3790576A (en) * | 1972-03-20 | 1974-02-05 | Parke Davis & Co | 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008093639A1 (ja) * | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| JP2013536866A (ja) * | 2010-09-01 | 2013-09-26 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺菌・殺カビ性ピラゾールおよびその混合物 |
| WO2016204270A1 (ja) * | 2015-06-18 | 2016-12-22 | 日本曹達株式会社 | ジアリールアゾール化合物および有害生物防除剤 |
| JPWO2016204270A1 (ja) * | 2015-06-18 | 2018-02-08 | 日本曹達株式会社 | ジアリールアゾール化合物および有害生物防除剤 |
| US10548316B2 (en) | 2015-06-18 | 2020-02-04 | Nippon Soda Co., Ltd. | Diarylazole compound and harmful organism control agent |
| JP2020128397A (ja) * | 2015-06-18 | 2020-08-27 | 日本曹達株式会社 | ジアリールアゾール化合物および有害生物防除剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003297565A1 (en) | 2004-06-23 |
| TW200418803A (en) | 2004-10-01 |
| WO2004050651A1 (en) | 2004-06-17 |
| HK1087103A1 (zh) | 2006-10-06 |
| HN2003000379A (es) | 2005-12-20 |
| AU2003295890A1 (en) | 2004-06-23 |
| US20040157904A1 (en) | 2004-08-12 |
| UY28098A1 (es) | 2004-06-30 |
| WO2004050650A1 (en) | 2004-06-17 |
| BR0316723A (pt) | 2005-10-18 |
| KR20050085170A (ko) | 2005-08-29 |
| US7265144B2 (en) | 2007-09-04 |
| CA2507186A1 (en) | 2004-06-17 |
| EP1567517A1 (en) | 2005-08-31 |
| AR042067A1 (es) | 2005-06-08 |
| MXPA05004621A (es) | 2005-06-08 |
| MY141528A (en) | 2010-05-14 |
| PE20040907A1 (es) | 2005-01-27 |
| PL377164A1 (pl) | 2006-01-23 |
| US20080064734A1 (en) | 2008-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080064734A1 (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| US20090209451A1 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| JP6948322B2 (ja) | Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン | |
| WO2020114482A1 (zh) | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 | |
| JP2001519811A (ja) | ソマトスタチン作働薬 | |
| JP2001502712A (ja) | 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト | |
| US8299066B2 (en) | Compounds having NPY Y5 receptor antagonistic activity | |
| JP2013534229A (ja) | バニロイド受容体リガンドとしての置換された環状カルボキサミド誘導体および尿素誘導体 | |
| JP2009506127A (ja) | 糖尿病の処置に有用なアニリノピラゾール誘導体 | |
| WO2019169193A1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| CN109748914B (zh) | 吡啶并嘧啶类化合物及其应用 | |
| US20080009531A1 (en) | 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes | |
| TW202340185A (zh) | Ampk活化劑 | |
| AU2017388300A1 (en) | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | |
| CN102361864A (zh) | 取代的3-苯并呋喃基-吲哚-2-酮-3-乙酰氨基哌嗪衍生物、其制备及其治疗用途 | |
| CN113943295B (zh) | 吡咯并嘧啶类化合物及其用途 | |
| HK1087103B (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| CN109280028B (zh) | 喹啉类化合物及其在dpp-4酶抑制剂的应用 | |
| CN109305957B (zh) | 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用 | |
| TW200916442A (en) | 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators | |
| MXPA06008833A (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| TW200911234A (en) | Compounds which inhibit the glycine transporter and uses thereof in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061116 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090731 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100420 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100720 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100727 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101019 |